We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 10 for:    CRS-207

Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03006302
Recruitment Status : Not yet recruiting
First Posted : December 30, 2016
Last Update Posted : August 29, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

This study will enroll patients who have metastatic pancreatic cancer and have progressed on prior chemotherapy.

Half of participants will receive epacadostat/pembrolizumab/cyclophosphamide(CY)/GVAX pancreas vaccine followed by epacadostat/pembrolizumab/CRS-207 (Arm A), while the other half will receive epacadostat/pembrolizumab/CRS-207 (Arm B).

The primary objectives of this study are to determine the recommended dose of epacadostat in this combination and assess survival of subjects in both treatment groups.


Condition or disease Intervention/treatment Phase
Metastatic Pancreatic Adenocarcinoma Drug: Epacadostat Drug: Pembrolizumab Biological: CRS-207 Drug: CY Biological: GVAX Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer
Anticipated Study Start Date : September 2017
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : June 2023

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Epacadostat/Pembrolizumab/CY/GVAX/CRS-207 Drug: Epacadostat
50, 100, or 300 mg taken by mouth twice a day, every day of each cycle
Other Name: INCB024360
Drug: Pembrolizumab
200 mg IV on Day 1 of each cycle
Other Names:
  • MK-3475
  • anti-PD-1 mAb
Biological: CRS-207
1x10^9 CFU given IV on Day 2 of Cycles 3-6 (Arm A) or Day 2 of Cycles 1-6 (Arm B)
Drug: CY
200 mg/m^2 given IV on Day 1 of Cycles 1-2 (Arm A only)
Other Names:
  • cyclophosphamide
  • cytoxan
Biological: GVAX
5x10^8 cells given as 6 intradermal injections on Day 2 of Cycles 1-2 (Arm A only)
Other Names:
  • GVAX Pancreas Vaccine
  • Panc 10.05 pcDNA-1/GM-Neo, Panc 6.03 pcDNA-1/GM-Neo
Experimental: Epacadostat/Pembrolizumab/CRS-207 Drug: Epacadostat
50, 100, or 300 mg taken by mouth twice a day, every day of each cycle
Other Name: INCB024360
Drug: Pembrolizumab
200 mg IV on Day 1 of each cycle
Other Names:
  • MK-3475
  • anti-PD-1 mAb
Biological: CRS-207
1x10^9 CFU given IV on Day 2 of Cycles 3-6 (Arm A) or Day 2 of Cycles 1-6 (Arm B)


Outcome Measures

Primary Outcome Measures :
  1. Recommended Dose of Epacadostat [ Time Frame: 1 year ]
    Evaluate 3 dose levels of epacadostat, in order to determine recommended dose for use in combination with pembrolizumab, CY, GVAX, and CRS-207

  2. 6 Month Survival [ Time Frame: 4 years ]
    Proportion of subjects who are alive 6 months or longer after the date of randomization


Secondary Outcome Measures :
  1. Number of patients experiencing treatment related toxicities [ Time Frame: 4 years ]
  2. Overall Survival (OS) [ Time Frame: 4 years ]
    Average time from randomization to death due to any cause

  3. Progression Free Survival (PFS) [ Time Frame: 4 years ]
    Average time from randomization to disease progression (by RECIST 1.1) or death, whichever comes first

  4. immune-related Progression Free Survival (irPFS) [ Time Frame: 4 years ]
    Average time from randomization to disease progression (by irRC) or death, whichever comes first.

  5. Objective Response Rate (ORR) [ Time Frame: 4 years ]
    Proportion of subjects who achieve a Complete Response (CR) or Partial Response (PR) by RECIST 1.1

  6. immune-related Objective Response Rate (irORR) [ Time Frame: 4 years ]
    Proportion of subjects who achieve a Complete Response (CR) or Partial Response (PR) by irRC

  7. Best Overall Response (BOR) [ Time Frame: 4 years ]
    Summary of the best response (by RECIST 1.1) achieved by each patient

  8. immune-related Best Overall Response (irBOR) [ Time Frame: 4 years ]
    Summary of the best response (by irRC) achieved by each patient

  9. Time to Objective Response (TTOR) [ Time Frame: 4 years ]
    Average time from randomization to partial or complete response by RECIST 1.1

  10. immune-related Time to Objective Response (irTTOR) [ Time Frame: 4 years ]
    Average time from randomization to partial or complete response by irRC

  11. Duration of Response (DOR) [ Time Frame: 4 years ]
    Average time from partial or complete response to disease progression, by RECIST 1.1

  12. immune-related Duration of Response (irDOR) [ Time Frame: 4 years ]
    Average time from partial or complete response to disease progression, by irRC

  13. Duration of Clinical Benefit (DCB) [ Time Frame: 4 years ]
    Average time from randomization to date of disease progression in subjects achieving a partial or complete response by RECIST 1.1

  14. immune-related Duration of Clinical Benefit (irDCB) [ Time Frame: 4 years ]
    Average time from randomization to date of disease progression in subjects achieving a partial or complete response by RECIST 1.1

  15. Disease Control Rate (DCR) [ Time Frame: 4 years ]
    Percentage of subjects achieving stable disease or better by RECIST 1.1

  16. immune-related Disease Control Rate (irDCR) [ Time Frame: 4 years ]
    Percentage of subjects achieving stable disease or better by irRC

  17. Tumor Marker (CA19-9) Kinetics [ Time Frame: 4 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (abbreviated):

  • Documented adenocarcinoma of the pancreas
  • Have disease progression after prior chemotherapy for metastatic pancreas cancer (or adjuvant or neoadjuvant if progression occurred within 6 months of completing this regimen)
  • Presence of at least one measurable lesion
  • Patient acceptance to have a tumor biopsy of an accessible lesion at 2 time points (baseline and on study)
  • ECOG performance status of 0 or 1
  • Life expectancy of greater than 3 months
  • Adequate organ and marrow function defined by study-specified laboratory tests

Exclusion Criteria (abbreviated):

  • Brain metastases
  • Clinical or radiographic ascites (some trace amount may be allowed)
  • Rapidly progressing disease
  • Live vaccine within 30 days of study treatment (flu vaccine allowed)
  • Surgery within 28 days of study treatment (some exceptions for minor procedures)
  • Use of an investigational agent or device within 28 days of study treatment.
  • Chemotherapy, radiation, or biological cancer therapy within 14 days of study treatment.
  • Prior treatment with anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti PD-L2, or with IDO inhibitor.
  • Use of growth factors within 14 days of study treatment
  • Use of any systemic steroids within 14 days of study treatment or other immunosuppressive agents within 7 days of study treatment.
  • Use of more than 2 g/day of acetaminophen
  • Use of any UGT1A9 inhibitor
  • Use of warfarin
  • Use of MAOIs or drugs with significant MAOI activity within the 21 days of screening
  • History of Seratonin Syndome
  • Known allergy to both penicillin and sulfa
  • Known or suspected hypersensitivity to any monoclonal antibody or any study drug component
  • Have artificial joints or implants that cannot be easily removed or a history of infection associated with an implant
  • Significant or malignant pleural effusion
  • New pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within 2 months of study enrollment
  • History of autoimmune disease (exceptions for Graves or Hashimoto's disease, vitiligo, and type I diabetes mellitus)
  • Gastrointestinal condition that may affect drug absorption
  • Significant heart disease or heart disease requiring antibiotic for prevention of endocarditis
  • History of abnormal electrocardiogram (ECG) that is deemed meaningful by the investigator
  • History of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis
  • Pulse oximetry of < 92% on room air or the need for supplemental home oxygen
  • Infection with HIV, hepatitis B or hepatitis C
  • Other conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access that would affect the patient's ability to comply with study visits and procedures
  • Pregnant or breastfeeding women
  • Unwillingness or inability to follow the study schedule for any reason
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03006302


Contacts
Contact: Susan Sartorius-Mergenthaler, R.N. 410-614-3644 sartosu@jhmi.edu

Locations
United States, Maryland
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting
Baltimore, Maryland, United States, 21287
Contact: SKCCC - Clinical Trials Office    410-955-8804    jhcccro@jhmi.edu   
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
Investigators
Principal Investigator: Dung Le, M.D. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
More Information

Responsible Party: Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT03006302     History of Changes
Other Study ID Numbers: J16173
IRB00118520 ( Other Identifier: JHMIRB )
First Posted: December 30, 2016    Key Record Dates
Last Update Posted: August 29, 2017
Last Verified: May 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
pancreatic cancer
vaccine
immunotherapy
MK-3475
PD-1
IDO

Additional relevant MeSH terms:
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Vaccines
Cyclophosphamide
Pembrolizumab
Pancrelipase
Pancreatin
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Gastrointestinal Agents